Abstract: Cancer care delivery is safe and feasible using an approach focused on careful patient selection, team communication and infection control.
Introduction
During the initial peak of the COVID-19 pandemic in Spring 2020, New York City—and specifically the Bronx—emerged as a global epicenter. For healthcare providers, this period presented a critical dilemma: cancer patients are uniquely vulnerable to severe viral outcomes due to disease- and treatment-related immunosuppression, yet their oncological care is highly time-sensitive. Delaying chemotherapy or immunotherapy can lead to fatal disease progression.
This study details the operational strategies and clinical outcomes at Lincoln Medical and Mental Health Center, a public teaching hospital in the Bronx. By implementing rigorous infection control and multidisciplinary triage, the facility aimed to maintain essential outpatient oncology services while protecting this high-risk population.
Operational Methods and Infection Control
To maintain the safety of the outpatient oncology infusion center, the hospital implemented a multi-layered protocol focused on communication and physical safety:
- Multidisciplinary Team Huddles: The staff conducted twice-daily huddles involving oncologists, pharmacists, nurses, and social workers. these meetings were essential for reviewing the risk-benefit ratio for each patient and adapting to rapidly changing institutional and CDC guidelines.
- Rigorous Screening: Patients underwent telephone screening 24 hours prior to their appointments, followed by secondary screening at the clinic entrance. Symptomatic patients were immediately isolated and triaged.
- Strategic Patient Selection: Treatments were deferred for patients where the immediate risk of COVID-19 exposure was deemed to outweigh the short-term benefit of their specific oncological therapy.
- Environmental Controls: The clinic mandated personal protective equipment (PPE) for all staff and patients, enforced physical distancing of at least six feet between infusion chairs, and implemented enhanced sanitization protocols.
Patient Population and Clinical Characteristics
The study cohort included 170 patients who accounted for 576 total visits between March 1 and May 7, 2020. The population was predominantly Hispanic (44%) and African American (41%), reflecting the demographics of the Bronx.
As shown in the table above, the median age was 60.7 years, and the majority of patients (79%) were being treated for solid organ malignancies. Notably, the cohort presented with significant comorbidities, with a median Charlson Comorbidity Index (CCI) of 6.6.
Key Results and Risk Factors
The primary finding of the study was that outpatient cancer care could be delivered with a low rate of severe infection. Out of the 170 patients treated, only 6 (3.5%) developed severe COVID-19 requiring hospitalization. Among these six cases, two patients died, three recovered, and one transitioned to hospice due to cancer progression.
Statistical analysis using multiple logistic regression identified specific risk factors for severe outcomes:
- Diabetes as a Primary Driver: A history of diabetes was the strongest predictor of severe COVID-19, with an Odds Ratio of 25.9 (p = 0.033).
- Comorbidity Burden: The six patients who developed severe COVID-19 had a median CCI of 9, significantly higher than the cohort average of 6.6.
- Treatment Safety: Interestingly, the type of malignancy (solid vs. hematological) and the type of systemic therapy (cytotoxic chemotherapy vs. immunotherapy or targeted therapy) did not significantly increase the risk of severe COVID-19 in this cohort.
Discussion and Limitations
The experience at this Bronx teaching hospital suggests that the "team huddle" approach and strict infection control allow for the safe continuation of life-saving cancer treatments even during a pandemic peak. The data highlights that underlying metabolic health, specifically diabetes, may be a more significant risk factor for cancer patients than the immunosuppressive treatments themselves.
However, the study has limitations, including a relatively small sample size and a retrospective design. Due to limited testing availability in early 2020, asymptomatic or mild cases were likely underreported. Future research is needed to further explore the interaction between diabetes and COVID-19 severity in oncological populations, as well as the long-term safety of immune checkpoint inhibitors during viral outbreaks.
Summary updated